NORDICENDOTROPHIN
DEAD

Serial Number

79405513

Owner

Nordic Bioscience A/S

Filing Date

Aug 23, 2024

Add to watchlist:

No watchlists yet
View on USPTO

NORDICENDOTROPHIN Trademark

Serial Number: 79405513

NORDICENDOTROPHIN is a trademark filed by Nordic Bioscience A/S on August 23, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Nordic Bioscience A/S (10 trademarks)

Herlev Hovedgade 205-207

Entity Type: 99

Trademark Details

Filing Date

August 23, 2024

Registration Date

Not Registered

Goods & Services

Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; advice, information and assistance relating to the foregoing.

Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 19, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 2, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 2, 2026 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Oct 27, 2025 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Oct 27, 2025 ABN2
REFUSAL PROCESSED BY IB
May 4, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 12, 2025 RFCS
REFUSAL PROCESSED BY MPU
Apr 12, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 7, 2025 RFCR
NON-FINAL ACTION WRITTEN
Mar 6, 2025 CNRT
ASSIGNED TO EXAMINER
Feb 27, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 8, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 8, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 3, 2024 REPR